These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18506159)

  • 1. Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases.
    Langford CA
    Nat Clin Pract Rheumatol; 2008 Jul; 4(7):364-70. PubMed ID: 18506159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of tumour necrosis factor blockade in orphan diseases.
    Keystone EC
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii79-ii83. PubMed ID: 15479879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.
    Mukhtyar C; Luqmani R
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv31-6. PubMed ID: 16239383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations.
    Huugen D; Tervaert JW; Heeringa P
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1100-7. PubMed ID: 17699331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.
    Hoffman GS; Merkel PA; Brasington RD; Lenschow DJ; Liang P
    Arthritis Rheum; 2004 Jul; 50(7):2296-304. PubMed ID: 15248230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.
    Molloy ES; Langford CA; Clark TM; Gota CE; Hoffman GS
    Ann Rheum Dis; 2008 Nov; 67(11):1567-9. PubMed ID: 18677012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential target of infliximab in autoimmune and inflammatory diseases.
    Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic treatment of large-vessel vasculitides.
    Schäfer VS; Zwerina J
    Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics in vasculitides: Where do we stand, where do we go from now?
    Pazzola G; Muratore F; Pipitone N; Salvarani C
    Presse Med; 2015 Jun; 44(6 Pt 2):e231-9. PubMed ID: 26024760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-TNF alpha agents in vasculitis].
    Solans Laqué R; Bosch Gil JA
    Med Clin (Barc); 2008 Feb; 130(3):93-4. PubMed ID: 18261379
    [No Abstract]   [Full Text] [Related]  

  • 12. Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?
    Salvarani C; Pipitone N; Boiardi L; Hunder GG
    Ann Rheum Dis; 2008 May; 67(5):577-9. PubMed ID: 18408108
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature.
    Comarmond C; Plaisier E; Dahan K; Mirault T; Emmerich J; Amoura Z; Cacoub P; Saadoun D
    Autoimmun Rev; 2012 Jul; 11(9):678-84. PubMed ID: 22155781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists.
    Filocamo G; Buoncompagni A; Viola S; Loy A; Malattia C; Ravelli A; Martini A
    J Pediatr; 2008 Sep; 153(3):432-4. PubMed ID: 18718263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
    Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
    Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
    [No Abstract]   [Full Text] [Related]  

  • 16. TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases.
    Lamprecht P
    Autoimmun Rev; 2005 Jan; 4(1):28-34. PubMed ID: 15652776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotherapies in large vessel vasculitis.
    Ferfar Y; Mirault T; Desbois AC; Comarmond C; Messas E; Savey L; Domont F; Cacoub P; Saadoun D
    Autoimmun Rev; 2016 Jun; 15(6):544-51. PubMed ID: 26883459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biologic therapies in the systemic vasculitides].
    Díaz-Orta MA; Rojas-Serrano J
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S33-6. PubMed ID: 22152288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
    van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
    Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of large vessel vasculitis].
    Alvarez-Hernández E
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S28-32. PubMed ID: 22152287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.